About / Media Center
Trinity News
Filter by Type:
Pfizer’s Nurtec, AstraZeneca’s Breztri top pharma brand report
Trinity’s Jerry Luciano and Tim McLaughlin were featured in an article by MM+M titled, “Pfizer’s Nurtec, AstraZeneca’s Breztri top pharma brand report.” The article focuses on the findings of the fourth annual TGaS Digital Marketing Competency Report. Read the article to...
2024 Digital Insights: Pfizer’s Nurtec and AstraZeneca’s Breztri Shine
Trinity Life Sciences’ fourth annual TGaS Digital Marketing Competency Report was featured in an article published on Investors Hangout.
How to achieve a successful drug launch in the first year
Trinity’s Krista Perry, Partner & Head of Launch Excellence, was featured in an article by MM+M titled, “How to achieve a successful drug launch.” Read the article to learn more about what factors contribute to a successful drug launch.
The Challenges and Opportunities in Clinical Trial Diversity: Mistrust in the healthcare system is a significant barrier to recruitment
Trinity’s Lisa Bailey, Ph.D., Managing Director of Insights & Head of DEI Strategy, authored an article that was published in Drug Discovery Today. Read the article, “The Challenges and Opportunities in Clinical Trial Diversity: Mistrust in the healthcare system is a...
Drugs for unmet needs and those from experienced companies had the best chance for successful launches in 2023: report
Trinity’s Krista Perry, Partner & Head of Launch Excellence, was featured in an article by Fierce Pharma to discuss our latest white paper, Moving the Needle: Lessons from the 2023 Launch Class. Read the article to learn more about what factors...
Half of US meds launched in 2023 ‘underperformed’
Trinity Life Sciences’ recent white paper on the first year performance of the 2023 launch class was featured in an article published on The Pharma Letter.
Precision, planning and creativity for launch excellence in a volatile sector
Trinity’s recent white paper, Picking Winners: Portfolio Management for a New Era, was mentioned in a recent article by Pharmaceutical Market Europe.
How biopharma companies can make the best choices
The biopharma industry is intensely competitive, and companies must go to great lengths to gain any commercial edge. However, it is also an industry that sees more failure than success. Leslie Orne, President & CEO of Trinity Life Sciences, provides an...
Big savings? Analyzing the IRA’s impact on the industry
Trinity Life Science’s Monica Martin De Bustamante analyzes the Medicare-negotiated prices of the first 10 drugs under the Inflation Reduction Act.
People on the Move in Boston: Nancy Phelan
Check out Nancy Phelan’s profile in the Boston Business Journal.
Finding the Trust in Clinical Trials: Q&A with Lisa Bailey
It’s clear that there is still work to be done with regard to diversity in clinical trials. Lisa Bailey, Managing Director and Head of DEI Strategy at Trinity Life Sciences, shares her insights with Pharmaceutical Executive on the lack of diversity...
Balancing Risk and Opportunity to Choose Winning Therapies
“While FDA approval has long been a singular prize, companies should also mine their assets for the strongest commercial opportunities. …the ability to take a drug to market is an important milestone, but it is not the entire picture. To truly...